EMA backs approval of Bavarian Nordic's vaccine for monkeypox disease

22 July 2022

The European Medicines Agency’s ’s human medicines committee (CHMP) has recommended extending the indication of the smallpox vaccine Imvanex, developed by Denmark’s Bavarian Nordic (OMX: BAVA), to include protecting adults from monkeypox disease.

Bavarian Nordic, whose shares closed up more than 5% at 334.00 kroner following the EMA announcement, has already signed a number of supply contracts for the vaccine with various European countries. Since May this year, monkeypox has been spreading into Europe and elsewhere, from Nigeria where it is endemic.

Imvanex is marketed as Jynneos in the USA where it is authorized for the prevention of both monkeypox and smallpox.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK